Nucala was first approved for the treatment of severe asthma with eosinophilic phenotype in the usa in 2015.
Zhixun Finance app learned that GlaxoSmithKline (GSK.US) announced that its "first-in-class" monoclonal antibody therapy, Nucala (mepolizumab), achieved positive results in the phase 3 clinical trial MATINEE for the treatment of adults with chronic obstructive pulmonary disease (COPD). This trial result will support GSK in discussions with regulatory institutions to submit applications for the expansion of Nucala's indications.
The MATINEE trial met its primary endpoint. Nucala, when added to inhaled maintenance therapy, significantly reduced the annualized rate of moderate/severe disease exacerbations compared to placebo, with clinically meaningful differences.
Nucala was first approved for the treatment of severe asthma with eosinophilic phenotype in the usa in 2015. It is a monoclonal antibody targeting IL-5, and has been developed for the treatment of a range of IL-5 mediated diseases associated with Type 2 inflammation.